Objective — to evaluate the clinical, endoscopic, microbiological and morphological efficacy and safety of rebamipide in the prevention of gastro‑ and enterocolopathy in patients with osteoarthritis taking non‑steroidal anti‑inflammatory drugs (NSAIDs). Materials and methods. A multicenter, randomized, comparative study in parallel groups was conducted to investigate the efficacy and safety of rebamipide (Mukogen) in the prevention of NSAID‑induced gastro‑ and enterocolopathy in patients with deformative osteoarthritis taking NSAIDs. We observed 123 patients with osteoarthritis (OA) aged 42 to 67 years (mean age 56.2±4.3 years). Among them, 55 were women and 68 were men. The diagnosis of OA was made at least 12 months before inclusion in the study. All patients had generalized OA with involvement of more than 3 large joints, among which at least 1 joint had radiological stage III OA. Patients received chondroprotectors as basic therapy for the underlying disease. In addition, patients used disease‑modifying osteoarthritis drugs — NSAIDs. Over the past 6 months before inclusion in the study, patients took non‑selective NSAIDs on average at least 1—2 times a week, and in case of exacerbation of OA with joint pain at least 1 time per day. The examined patients underwent a non‑invasive hydrogen breath test before and after therapy to analyze the presence of bacterial overgrowth syndrome. In addition, the patients underwent fibrogastroduodenoscopy and colonoscopy, during one visit with the use of propofol for sedation and anesthesia. During endoscopy, a biopsy of the mucosa of the stomach and large intestine was performed. After the examination, only 100 OA patients were included in the study. OA patients were randomly divided into 2 groups: Group I (50 patients) — OA patients receiving basic therapy and rebamipide (Mukogen) 300 mg per day for 12 weeks. Group II (50 patients) — OA patients receiving basic therapy and proton pump inhibitor 20 mg per day for 12 weeks. Results. Patients with a high and medium risk of NSAID‑induced gastropathy and enterocolopathy predominated in the group of patients with OA, which requires additional stratification before prescribing NSAIDs. Clinical manifestations of gastropathy are detected in a third, and enterocolopathy in half of patients taking NSAIDs, the clinical picture is nonspecific and the symptoms have low intensity. Endoscopic changes in the gastric and intestinal mucosa in patients with NSAID‑gastro‑enterocolopathy are more common than its clinical manifestations. The presence of endoscopic changes correlates with the degree of risk. Morphological changes in the gastric and intestinal mucosa are detected in almost all patients taking NSAIDs and are characterized by the presence of damage to the surface epithelium and hemorrhages with stromal edema with inflammatory cell infiltration and gland atrophy, which correlates with the degree of risk of NSAID‑induced gastrointestinal lesions. This is combined with disturbances in the quantitative and qualitative composition of mucus and increased permeability of the epithelial mucosal barrier of the stomach and intestines. Disturbances of the mucosal barriers of the gastrointestinal tract with increased epithelial permeability and bacterial overgrowth syndrome can be considered as additional pathogenetic mechanisms of the development of NSAID‑induced gastro‑ and enterocolopathy. Conclusions. Evaluation of the appointment of Mucogen with analysis of clinical and endoscopic, morphological efficacy, effect on the gastrointestinal mucosal barrier with modification, epithelial permeability, mucus formation and bacterial overgrowth syndrome proved its greater effectiveness compared to proton pump inhibitors for the complex prevention and treatment of NSAID‑induced gastro‑ and enterocolopathy in patients with osteoarthritis.